What happened
FDA states that its April 13 to 17, 2026 inspection of Shoolin Pharma Chem LLP found APIs prepared, packed, or held under insanitary conditions and identified significant API CGMP violations. Investigators observed layered unidentified residues, chemical residues and stains on walls, floors, equipment, and product-contact areas; corroded or apparently rusted surfaces; leaking lines; improperly stored transfer lines; and an employee wearing open-toed sandals near open equipment during production. Nondedicated equipment was used for multiple APIs. FDA also found inadequate written cleaning and maintenance procedures, no swab or rinse cleaning verification, and insufficient cleaning validation remediation. The firm could not provide raw data supporting certificate-of-analysis results, while contract-laboratory results were reported on company letterhead without identifying the original laboratory. Stability chambers were powered off or outside temperature or humidity conditions, supporting records were unavailable, and tadalafil samples were missing. FDA further cited inadequate quality-unit oversight of impurity risks, contract laboratories, process validation, equipment calibration, materials testing, and annual product reviews. The firm recalled all APIs distributed in the U.S., and FDA placed its drugs on Import Alert 66-40.
Why it matters
From a GMP and pharmaceutical manufacturing perspective, residues, corrosion, leakage, inadequate gowning, and unverified cleaning on nondedicated equipment may create cross-contamination and product-quality risks. Missing original laboratory data may prevent reliable confirmation that materials and APIs met specifications, while deficient chamber control and missing stability samples may undermine assigned expiry dates. Weak quality-unit oversight may allow deficiencies to persist across production and testing. FDA noted substantial uncertainty in retrospectively defining contamination and stated that retain-sample testing alone was insufficient to determine its scope.
Key topics: Insanitary conditions and cross-contamination hazards in nondedicated API equipment, Missing laboratory raw data supporting certificates of analysis, Deficient stability program and ineffective quality-unit oversight